In this issue:
Infections in immunomodulator and biologic recipients not due to high drug concentrations
Adding allopurinol to thiopurine in IBD escalating to immunomodulators
Switching intravenous to subcutaneous infliximab in IBD treated with intensified doses
Dietary nutrient index and IBD risk
Extended induction and maintenance upadacitinib for moderate-to-severe UC
Modified Rutgeerts for predicting long-term outcomes after primary ileocaecal resection in CD
Intestinal barrier biomarkers in clinical evaluation of IBD patients
Vedolizumab vs. infliximab in biologic-naive CD
Durability of first biologic in CD
Withdrawal and retreatment with filgotinib in UC
Please login below to download this issue (PDF)